Advances in the management of hyperlipidemia-induced atherosclerosis

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Although hyperlipidemia clearly plays a role in developing cardiovascular disease, the 10% of the population with the highest LDL levels account for only 20% of cardiovascular disease events. Thus, in order to significantly reduce the burden of cardiovascular disease, subjects with only modest dyslipidemia need to be treated with lipid-lowering therapy. Current guidelines have recommended aggressive lipid-lowering therapy in subjects at high risk of cardiovascular disease. The rationale behind this and treatment options to achieve target lipid goals are discussed.

Original languageEnglish
Pages (from-to)369-383
Number of pages15
JournalExpert Review of Cardiovascular Therapy
Issue number3
StatePublished - Mar 2008


  • Atherosclerosis
  • Cardiovascular
  • Cholesterol
  • Fibrate
  • Low-density lipoprotein
  • Nicotinic acid
  • Statin

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Advances in the management of hyperlipidemia-induced atherosclerosis'. Together they form a unique fingerprint.

Cite this